Press Release

<< Back
Synta Pharmaceuticals Appoints Christopher J. Logothetis, M.D., Mace L. Rothenberg, M.D., and Daniel D. Von Hoff, M.D., F.A.C.P. to Oncology Advisory Board

LEXINGTON, MA – June 25, 2004 – Synta Pharmaceuticals Corp., an emerging pharmaceutical company, today announced the appointments of Christopher J. Logothetis, M.D., Mace L. Rothenberg, M.D., and Daniel D. Von Hoff, M.D., F.A.C.P. to its newly formed Oncology Advisory Board. Synta formed the Oncology Advisory Board to access world-class knowledge and insight in all of its clinical development programs for oncology products.

“I am delighted that Drs. Logothetis, Rothenberg and Von Hoff have joined Synta's Oncology Advisory Board,” stated Dr. Matthew Sherman, Senior Vice President and Chief Medical Officer. “Together, they comprise an enormous base of knowledge in multidisciplinary clinical research and cancer drug development expertise. As leaders in their fields, I look forward to working together with the Board to accelerate the advancement of Synta's multi-product oncology development portfolio.”

Dr. Logothetis is Professor and Chairman of the Department of Genitourinary Medical Oncology at The University of Texas M. D. Anderson Cancer Center, Houston, Texas and is Principal Investigator of the M. D. Anderson SPORE in Prostate Cancer. He is also Director of the Genitourinary Cancer Center and the Prostate Cancer Research Program, which are multidisciplinary collaborations of physicians and scientists dedicated to genitourinary cancer treatment, research, prevention, and education. Among other responsibilities, Dr. Logothetis is a leader in the Therapy Consortium, an active group of researchers involved in the development of innovative therapy for prostate cancer. He is an internationally recognized leader in prostate cancer research.

Dr. Rothenberg is Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center and Professor of Medicine at Vanderbilt University Medical Center, in Nashville, Tennessee. He is also a practicing physician with appointments at the Vanderbilt University Medical Center and the Department of Veterans Affairs Medical Center. Dr. Rothenberg is the Director of the Phase I Drug Development Program at Vanderbilt-Ingram Cancer Center and he serves on a number of committees including the Vanderbilt-Ingram Cancer Center Gastrointestinal Cancer SPORE Executive Committee and Lung Cancer SPORE Steering Committee, the Clinical Cancer Research Committee for the American Association for Cancer Research, and the Medical Oncology Committee for the American College of Surgeons. He also serves on the editorial boards of seven peer-reviewed journals and has authored over 100 scientific and clinical publications.

Dr. Von Hoff is Professor of Medicine, Molecular and Cellular Biology, and Pathology at the University of Arizona in Tuscon, Arizona and is also Clinical Professor in the College of Pharmacy at The University of Texas at Austin in Austin, Texas. He is Director of the Cancer Therapeutics Program at the Arizona Health Sciences Center and Director of the Translational Drug Development Division at the Translational Genomics Institute. Dr. Von Hoff was involved in the development of many successful anticancer agents, including mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, and CPT-11. He is past president of the American Association for Cancer Research and past board member of the American Society of Clinical Oncology. Dr. Von Hoff founded and is currently editor emeritus of Investigational New Drugs – The Journal of New Anticancer Agents. He serves on the editorial boards of nine academic publications and has published more than 470 papers, 120 book chapters, and 800 abstracts.

About Synta

Synta Pharmaceuticals is an emerging pharmaceutical company focused on discovering, developing, and commercializing breakthrough products for severe medical conditions. Synta has a diverse pipeline of small-molecule therapeutics for the treatment of cancer and immune disorders, with its two most advanced products in Phase II clinical development. Synta developed as a buyout of the U.S. subsidiary of a large Japanese pharmaceutical company. As a result, Synta has an experienced and successful drug discovery team that has worked together for over ten years. All clinical candidates were developed by this team using Synta's chemistry-driven drug discovery platform. Synta fully owns all rights for all of its products. For more information, please see